Failure of second challenge with mogamulizumab in C-C chemokine receptor 4-positive cutaneous T-cell lymphoma

被引:0
作者
Stammler, Romain [1 ,5 ]
Ta, Van Anh [6 ,7 ]
Cohen, Elisabeth [6 ]
Ram-Wolff, Caroline [1 ]
Bozonnat, Alizee [1 ,5 ,7 ]
Battesti, Gilles [1 ,5 ,7 ]
Louveau, Baptiste [2 ,5 ,7 ]
Mourah, Samia [2 ,5 ,7 ]
Battistella, Maxime [3 ,5 ,7 ]
Moins-Teisserenc, Helene [4 ,6 ,7 ]
de Masson, Adele [1 ,5 ,7 ]
机构
[1] St Louis Hosp, AP HP, Dept Dermatol, Paris, France
[2] St Louis Hosp, AP HP, Dept Pharmacogen & Tumor Genom, Paris, France
[3] St Louis Hosp, AP HP, Dept Pathol, Paris, France
[4] St Louis Hosp, AP HP, Haematol Lab, Paris, France
[5] INSERM, U976, Paris, France
[6] INSERM, U1160, Inst Rech St Louis, Paris, France
[7] Univ Paris Cite, Paris, France
关键词
ANTIBODY;
D O I
10.1093/bjd/ljae085
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We report three patients with Sezary syndrome who had previously been successfully treated with mogamulizumab and then failed a second course of the same treatment, despite positive CCR4 expression at the second initiation of mogamulizumab. This suggests that secondary resistance of blood disease to mogamulizumab may be independent of target expression.
引用
收藏
页码:e95 / e95
页数:2
相关论文
共 7 条
[1]   Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma [J].
Beygi, Sara ;
Duran, George E. ;
Fernandez-Pol, Sebastian ;
Rook, Alain H. ;
Kim, Youn H. ;
Khodadoust, Michael S. .
BLOOD, 2022, 139 (26) :3732-3736
[2]   New biotherapies for the treatment of cutaneous T-cell lymphomas [J].
de Masson, A. .
PRESSE MEDICALE, 2022, 51 (01)
[3]   Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma [J].
Duvic, Madeleine ;
Pinter-Brown, Lauren C. ;
Foss, Francine M. ;
Sokol, Lubomir ;
Jorgensen, Jeffrey L. ;
Challagundla, Pramoda ;
Dwyer, Karen M. ;
Zhang, Xiaoping ;
Kurman, Michael R. ;
Ballerini, Rocco ;
Liu, Li ;
Kim, Youn H. .
BLOOD, 2015, 125 (12) :1883-1889
[4]   Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [J].
Kim, Youn H. ;
Bagot, Martine ;
Pinter-Brown, Lauren ;
Rook, Alain H. ;
Porcu, Pierluigi ;
Horwitz, Steven M. ;
Whittaker, Sean ;
Tokura, Yoshiki ;
Vermeer, Maarten ;
Zinzani, Pier Luigi ;
Sokol, Lubomir ;
Morris, Stephen ;
Kim, Ellen J. ;
Ortiz-Romero, Pablo L. ;
Eradat, Herbert ;
Scarisbrick, Julia ;
Tsianakas, Athanasios ;
Elmets, Craig ;
Dalle, Stephane ;
Fisher, David C. ;
Halwani, Ahmad ;
Poligone, Brian ;
Greer, John ;
Fierro, Maria Teresa ;
Khot, Amit ;
Moskowitz, Alison J. ;
Musiek, Amy ;
Shustov, Andrei ;
Pro, Barbara ;
Geskin, Larisa J. ;
Dwyer, Karen ;
Moriya, Junji ;
Leoni, Mollie ;
Humphrey, Jeffrey S. ;
Hudgens, Stacie ;
Grebennik, Dmitri O. ;
Tobinai, Kensei ;
Duvic, Madeleine .
LANCET ONCOLOGY, 2018, 19 (09) :1192-1204
[5]   Multicenter Phase II Study of Mogamulizumab ( KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma [J].
Ogura, Michinori ;
Ishida, Takashi ;
Hatake, Kiyohiko ;
Taniwaki, Masafumi ;
Ando, Kiyoshi ;
Tobinai, Kensei ;
Fujimoto, Katsuya ;
Yamamoto, Kazuhito ;
Miyamoto, Toshihiro ;
Uike, Naokuni ;
Tanimoto, Mitsune ;
Tsukasaki, Kunihiro ;
Ishizawa, Kenichi ;
Suzumiya, Junji ;
Inagaki, Hiroshi ;
Tamura, Kazuo ;
Akinaga, Shiro ;
Tomonaga, Masao ;
Ueda, Ryuzo .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (11) :1157-+
[6]   Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma [J].
Ollila, Thomas A. ;
Sahin, Ilyas ;
Olszewski, Adam J. .
ONCOTARGETS AND THERAPY, 2019, 12 :1085-1094
[7]   Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome [J].
Roelens, Marie ;
de Masson, Adele ;
Andrillon, Anais ;
Ram-Wolff, Caroline ;
Biard, Lucie ;
Boisson, Marie ;
Mourah, Samia ;
Battistella, Maxime ;
Toubert, Antoine ;
Bagot, Martine ;
Moins-Teisserenc, Helene .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (06) :1010-1025